CliffBio
biologic

YIMMUGO

immune globulin intravenous, human-dira

Loss of exclusivityJune 2036projected — 12-year biologic exclusivity estimate
CompanyBiotest AG →See this company's full patent-cliff portfolio

Drug detail

Brand nameYIMMUGO
Active ingredientimmune globulin intravenous, human-dira
Strength10G/100ML
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJune 2024
Marketing statusRx

More from Biotest AG

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

YIMMUGO patent cliff — loss of exclusivity June 2036 | CliffBio